|Articles|November 1, 2001

Understanding the Hormone Continuum: From Menarche to Menopause
Volume 7
Issue 18 Suppl

Pharmacologic Characteristics of Progestins Used for Contraception and Hormone Replacement Therapy, Including New Transdermal Technologies

Download PDF: Pharmacologic Characteristics of Progestins Used for Contraception and Hormone Replacement Therapy, Including New Transdermal Technologies

Articles in this issue

over 24 years ago

Article

Introduction

over 24 years ago

Article

The Managed Care Pharmacy Perspective

over 24 years ago

Article

Managing the Transition from Oral Contraceptives to Hormone Replacement Therapy

over 24 years ago

Article

Patient Communication and Counseling on Contraception and Hormone Replacement Therapy

over 24 years ago

Article

CPE Quiz

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Impact of Automated Insulin Delivery on Type 2 Diabetes Measures

ByThomas W. Martens, MD,Bimal V. Patel, PharmD, MS,Sharon M. Wang, PharmD, MS,Laurel H. Messer, PhD, MPH, RN, CDCES, BC-ADM,Jordan E. Pinsker, MD,Daniel C. Malone, PhD, RPh,Miranda R. Polin, MS, BS,Diana I. Brixner, PhD, RPh,Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES,Osagie Ebekozien, MD, MPH

July 23rd 2026

Geographical Access to Preferred Pharmacies in Medicare Part D

ByPinka Chatterji, PhD,Yiran Han, PhD,Chun-Yu Ho, PhD

July 22nd 2026

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

ByEmily A. Gadbois, PhD,Jennifer Bunker, MPH,Marguerite Daus, PhD, RN,Jamie M. Smith, PhD, RN,Emily Buss, MSN, RN,Christine D. Jones, MD, MS,Kali S. Thomas, PhD, MA

July 16th 2026

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

ByHeather L. Taylor, MPH, LDH,Ann M. Holmes, PhD,Nir Menachemi, PhD, MPH,Justin Blackburn, PhD

July 10th 2026

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

ByChristopher Scannell, MD, PhD,John A. Romley, PhD,Rebecca Myerson, PhD,Dana Goldman, PhD,Dima Mazen Qato, PharmD, PhD, MPH

July 9th 2026

Pharmacologic Characteristics of Progestins Used for Contraception and Hormone Replacement Therapy, Including New Transdermal Technologies

Articles in this issue

Related Content

Impact of Automated Insulin Delivery on Type 2 Diabetes Measures

Geographical Access to Preferred Pharmacies in Medicare Part D

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

Trending on AJMC

Jeff Hunnicutt to Bring Community Oncology Roots to New Role as Navista COO

New MINT Trial Analysis Favors Liberal Transfusion After MI

Contributor: State Leaders Need Real-World Evidence to Integrate Social Care at Scale

Nipocalimab Improves gMG Outcomes Across East Asian Subgroup

Drug Development-to-Reimbursement Timelines Show Little Progress Over a Decade